Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on developing, manufacturing, marketing and distributing pharmaceutical products. Co.'s segments are: Generics, which includes product families covering a range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products; and AvKARE, which provides pharmaceuticals, medical and surgical products and services. The AMRX stock yearly return is shown above.
The yearly return on the AMRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AMRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|